# Head-to-head Comparison of Empagliflozin and Dapagliflozin

> **NCT03748810** · — · COMPLETED · sponsor: **Chungbuk National University Hospital** · enrollment: 600 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT03748810
- **Lead sponsor:** Chungbuk National University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03748810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03748810, "Head-to-head Comparison of Empagliflozin and Dapagliflozin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03748810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*